Jianan Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jianan Pan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Hui Zhang
Department of Cardiology Zhongshan Hospital Fudan University Shanghai Institute of Cardiovascular Diseases Shanghai China
2 shared publicationsXiaozhen He
Department of Echocardiography Zhongshan Hospital Fudan University Shanghai Institute of Cardiovascular Diseases Shanghai China
2 shared publicationsXuejun Wang
Department of Cardiology Zhongshan Hospital Fudan University Shanghai Institute of Cardiovascular Diseases Shanghai China
2 shared publicationsYerui Zhang
Department of Echocardiography Zhongshan Hospital Fudan University Shanghai Institute of Cardiovascular Diseases Shanghai China
2 shared publications- Alex Chia Yu Chang
Department of Cardiology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication Hao Lin
Department of Cardiology Ninth People’s HospitalShanghai Jiao Tong University School of Medicine Shanghai China
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (10) , e70843
A serum proteomics‐based predictive model for steroid‐resistant immune checkpoint inhibitor associated myocarditis
Background: Immune checkpoint inhibitor–associated myocarditis (ICIAM) is one of the immune–related adverse events (irAEs) with low incidence but extremely high mortality. High–dose glucocorticoid pulse therapy remains the recommended initial treatment for patients with ICIAM. However, an inadequate response to corticosteroid therapy is observed in some patients, who are subsequently classified as having steroid‐resistant immune checkpoint inhibitor‐associated myocarditis (srICIAM). Early combination of second‐line immunosuppression may represent an effective therapeutic strategy. However, Biomarkers capable of identifying such patients before treatment are currently lacking. We therefore sought to characterize circulating inflammatory proteins associated with corticosteroid responsiveness and to derive a preliminary serum‐based prediction model for steroid‐resistant ICIAM (srICIAM). Methods: Serum specimens obtained from patients with ICIAM at baseline and after methylprednisolone treatment were analyzed to quantify circulating immune‐related proteins using an antibody‐based proteomic assay. We developed a preliminary model for the early identification of patients at risk of srICIAM using proteins selected by three complementary machine–learning algorithms and evaluated its discriminatory performance in an internal hold‐out cohort. Results: Pretreatment serum samples from 47 patients with ICIAM were used to establish a protein–based prediction model, with 33 patients assigned to model development and 14 to internal validation. Patients with a high srICIAM predictive score (≥.5625) based on CXCL9, TRANCE and MMP1 were more likely to show an inadequate early response to corticosteroid therapy and may warrant closer clinical monitoring and further evaluation. The analysis also revealed that several serum immune proteins decreased in patients with ICIAM after methylprednisolone therapy. Serum CXCL9 levels were positively correlated with lactate dehydrogenase (LDH) and cardiac troponin T (cTnT). Conclusion: Serum immune proteins were dynamically altered in patients with ICIAM after methylprednisolone therapy. The preliminary score may enable earlier recognition of patients at risk of an inadequate corticosteroid response.
- 6 October 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (10) , e70843
Open AccessA serum proteomics‐based predictive model for steroid‐resistant immune checkpoint inhibitor associated myocarditis
Background: Immune checkpoint inhibitor–associated myocarditis (ICIAM) is one of the immune–related adverse events (irAEs) with low incidence but extremely high mortality. High–dose glucocorticoid pulse therapy remains the recommended initial treatment for patients with ICIAM. However, an inadequate response to corticosteroid therapy is observed in some patients, who are subsequently classified as having steroid‐resistant immune checkpoint inhibitor‐associated myocarditis (srICIAM). Early combination of second‐line immunosuppression may represent an effective therapeutic strategy. However, Biomarkers capable of identifying such patients before treatment are currently lacking. We therefore sought to characterize circulating inflammatory proteins associated with corticosteroid responsiveness and to derive a preliminary serum‐based prediction model for steroid‐resistant ICIAM (srICIAM). Methods: Serum specimens obtained from patients with ICIAM at baseline and after methylprednisolone treatment were analyzed to quantify circulating immune‐related proteins using an antibody‐based proteomic assay. We developed a preliminary model for the early identification of patients at risk of srICIAM using proteins selected by three complementary machine–learning algorithms and evaluated its discriminatory performance in an internal hold‐out cohort. Results: Pretreatment serum samples from 47 patients with ICIAM were used to establish a protein–based prediction model, with 33 patients assigned to model development and 14 to internal validation. Patients with a high srICIAM predictive score (≥.5625) based on CXCL9, TRANCE and MMP1 were more likely to show an inadequate early response to corticosteroid therapy and may warrant closer clinical monitoring and further evaluation. The analysis also revealed that several serum immune proteins decreased in patients with ICIAM after methylprednisolone therapy. Serum CXCL9 levels were positively correlated with lactate dehydrogenase (LDH) and cardiac troponin T (cTnT). Conclusion: Serum immune proteins were dynamically altered in patients with ICIAM after methylprednisolone therapy. The preliminary score may enable earlier recognition of patients at risk of an inadequate corticosteroid response.
- 8 February 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (4) , 2110-2124
Protective Effect of Red Yeast Rice on Immune Checkpoint Inhibitors‐Related Atherosclerotic Progression Through Inhibiting Macrophage Inflammatory Response and T Lymphocytes Infiltration
Immune checkpoint inhibitors (ICIs) have prolonged cancer survival but exacerbated atherosclerotic cardiovascular disease (ASCVD). This research aims to interrogate the underlying mechanism of ICIs‐related atherosclerotic progression and the potential protective effect of Red Yeast Rice (RYR) on it. A tumor‐bearing atherosclerotic (TB‐AS) mouse model was established by subcutaneously injecting MC38 cells in male ApoE −/− mice fed a high‐fat diet (HFD). Intraperitoneal anti‐PD‐1 antibody (αPD‐1) with/without dietary RYR supplementation was administered during the model. Serum was separated for lipid and inflammation evaluation. Plaque assessment was quantified by histological staining. Bone marrow‐derived macrophages (BMDMs) were isolated, incubated in growth medium containing 5% serum from the mice model, and treated with ox‐LDL and RYR. Cell viability was accessed by CCK8 assay. Lipid staining was employed to assess lipid droplet accumulation. The apoptosis and polarization of BMDMs were analyzed using flow cytometry. Cytokine levels were determined by luminex multiplex assay. And finally, western blot was conducted for mechanism investigation. αPD‐1 significantly increased atherosclerotic lesion area, plaque lipid content, and macrophage/T‐cell infiltration versus untreated TB‐AS controls. These effects coincided with elevated pro‐inflammatory cytokines/chemokines and reduced anti‐inflammatory mediators. RYR co‐treatment attenuated these αPD‐1‐induced pro‐atherogenic changes. In vitro, compared with serum from TB‐AS mice, BMDMs cultured with serum from αPD‐1‐treated TB‐AS mice exhibited reduced cell viability, elevated pro‐inflammatory cytokine levels in culture supernatants, enhanced M1 polarization, and increased apoptosis levels. All these phenotypic changes were reversed by RYR treatment. Mechanistically, RYR significantly inhibited the RhoA‐mediated activation of NF‐κB and MAPK signaling, thereby suppressing the αPD‐1‐induced inflammatory response in BMDMs. αPD‐1 promotes ASCVD progression by enhancing macrophage inflammation and T‐cell recruitment within plaques. RYR mitigates these effects through RhoA inhibition, suggesting its therapeutic potential for improving cardiovascular outcomes in ICIs‐treated cancer patients with ASCVD.
- 8 February 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (4) , 2110-2124
Protective Effect of Red Yeast Rice on Immune Checkpoint Inhibitors‐Related Atherosclerotic Progression Through Inhibiting Macrophage Inflammatory Response and T Lymphocytes Infiltration
Immune checkpoint inhibitors (ICIs) have prolonged cancer survival but exacerbated atherosclerotic cardiovascular disease (ASCVD). This research aims to interrogate the underlying mechanism of ICIs‐related atherosclerotic progression and the potential protective effect of Red Yeast Rice (RYR) on it. A tumor‐bearing atherosclerotic (TB‐AS) mouse model was established by subcutaneously injecting MC38 cells in male ApoE −/− mice fed a high‐fat diet (HFD). Intraperitoneal anti‐PD‐1 antibody (αPD‐1) with/without dietary RYR supplementation was administered during the model. Serum was separated for lipid and inflammation evaluation. Plaque assessment was quantified by histological staining. Bone marrow‐derived macrophages (BMDMs) were isolated, incubated in growth medium containing 5% serum from the mice model, and treated with ox‐LDL and RYR. Cell viability was accessed by CCK8 assay. Lipid staining was employed to assess lipid droplet accumulation. The apoptosis and polarization of BMDMs were analyzed using flow cytometry. Cytokine levels were determined by luminex multiplex assay. And finally, western blot was conducted for mechanism investigation. αPD‐1 significantly increased atherosclerotic lesion area, plaque lipid content, and macrophage/T‐cell infiltration versus untreated TB‐AS controls. These effects coincided with elevated pro‐inflammatory cytokines/chemokines and reduced anti‐inflammatory mediators. RYR co‐treatment attenuated these αPD‐1‐induced pro‐atherogenic changes. In vitro, compared with serum from TB‐AS mice, BMDMs cultured with serum from αPD‐1‐treated TB‐AS mice exhibited reduced cell viability, elevated pro‐inflammatory cytokine levels in culture supernatants, enhanced M1 polarization, and increased apoptosis levels. All these phenotypic changes were reversed by RYR treatment. Mechanistically, RYR significantly inhibited the RhoA‐mediated activation of NF‐κB and MAPK signaling, thereby suppressing the αPD‐1‐induced inflammatory response in BMDMs. αPD‐1 promotes ASCVD progression by enhancing macrophage inflammation and T‐cell recruitment within plaques. RYR mitigates these effects through RhoA inhibition, suggesting its therapeutic potential for improving cardiovascular outcomes in ICIs‐treated cancer patients with ASCVD.
- Open Access
- 7 June 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (11) , e024582
p53‐Dependent Mitochondrial Compensation in Heart Failure With Preserved Ejection Fraction
Background: Heart failure with preserved ejection fraction (HFpEF) accounts for 50% of patients with heart failure. Clinically, HFpEF prevalence shows age and gender biases. Although the majority of patients with HFpEF are elderly, there is an emergence of young patients with HFpEF. A better understanding of the underlying pathogenic mechanism is urgently needed. Here, we aimed to determine the role of aging in the pathogenesis of HFpEF. Methods and Results: HFpEF dietary regimen (high‐fat diet + Nω‐Nitro‐L‐arginine methyl ester hydrochloride) was used to induce HFpEF in wild type and telomerase RNA knockout mice (second‐generation and third‐generation telomerase RNA component knockout), an aging murine model. First, both male and female animals develop HFpEF equally. Second, cardiac wall thickening preceded diastolic dysfunction in all HFpEF animals. Third, accelerated HFpEF onset was observed in second‐generation telomerase RNA component knockout (at 6 weeks) and third‐generation telomerase RNA component knockout (at 4 weeks) compared with wild type (8 weeks). Fourth, we demonstrate that mitochondrial respiration transitioned from compensatory state (normal basal yet loss of maximal respiratory capacity) to dysfunction (loss of both basal and maximal respiratory capacity) in a p53 dosage dependent manner. Last, using myocardial‐specific p53 knockout animals, we demonstrate that loss of p53 activation delays the development of HFpEF. Conclusions: Here we demonstrate that p53 activation plays a role in the pathogenesis of HFpEF. We show that short telomere animals exhibit a basal level of p53 activation, mitochondria upregulate mtDNA encoded genes as a mean to compensate for blocked mitochondrial biogenesis, and loss of myocardial p53 delays HFpEF onset in high fat diet + Nω‐Nitro‐L‐arginine methyl ester hydrochloride challenged murine model.
- 7 June 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (11) , e024582
Open Accessp53‐Dependent Mitochondrial Compensation in Heart Failure With Preserved Ejection Fraction
Background: Heart failure with preserved ejection fraction (HFpEF) accounts for 50% of patients with heart failure. Clinically, HFpEF prevalence shows age and gender biases. Although the majority of patients with HFpEF are elderly, there is an emergence of young patients with HFpEF. A better understanding of the underlying pathogenic mechanism is urgently needed. Here, we aimed to determine the role of aging in the pathogenesis of HFpEF. Methods and Results: HFpEF dietary regimen (high‐fat diet + Nω‐Nitro‐L‐arginine methyl ester hydrochloride) was used to induce HFpEF in wild type and telomerase RNA knockout mice (second‐generation and third‐generation telomerase RNA component knockout), an aging murine model. First, both male and female animals develop HFpEF equally. Second, cardiac wall thickening preceded diastolic dysfunction in all HFpEF animals. Third, accelerated HFpEF onset was observed in second‐generation telomerase RNA component knockout (at 6 weeks) and third‐generation telomerase RNA component knockout (at 4 weeks) compared with wild type (8 weeks). Fourth, we demonstrate that mitochondrial respiration transitioned from compensatory state (normal basal yet loss of maximal respiratory capacity) to dysfunction (loss of both basal and maximal respiratory capacity) in a p53 dosage dependent manner. Last, using myocardial‐specific p53 knockout animals, we demonstrate that loss of p53 activation delays the development of HFpEF. Conclusions: Here we demonstrate that p53 activation plays a role in the pathogenesis of HFpEF. We show that short telomere animals exhibit a basal level of p53 activation, mitochondria upregulate mtDNA encoded genes as a mean to compensate for blocked mitochondrial biogenesis, and loss of myocardial p53 delays HFpEF onset in high fat diet + Nω‐Nitro‐L‐arginine methyl ester hydrochloride challenged murine model.